Generation of enhanced stability factor VIM variants by replacement of charged residues at the A2 domain interface

Blood

Volumn 112, Issue 7, 2008, Pages 2761-2769

  Wakabayashi, Hironao ^a   Varfaj, Fatbardha ^b   DeAngelis, Jennifer ^a   Fay, Philip J ^a  

^a UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE; ASPARTIC ACID; BLOOD CLOTTING FACTOR 8A; GLUTAMIC ACID; VALINE; AMINO ACID; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 9A; MUTANT PROTEIN; THROMBIN;

AMINO ACID SUBSTITUTION; ANIMAL CELL; ARTICLE; CELL STRAIN BHK; CONTROLLED STUDY; NONHUMAN; PLASMA; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN STABILITY; THERMOSTABILITY; WILD TYPE; ANIMAL; BIOASSAY; CELL LINE; CHEMISTRY; DRUG EFFECT; HAMSTER; HUMAN; METABOLISM; POINT MUTATION; POLYACRYLAMIDE GEL ELECTROPHORESIS; PROTEIN TERTIARY STRUCTURE; TEMPERATURE; THERMODYNAMICS; WESTERN BLOTTING;

AMINO ACID SUBSTITUTION; AMINO ACIDS; ANIMALS; BIOLOGICAL ASSAY; BLOTTING, WESTERN; CELL LINE; CRICETINAE; ELECTROPHORESIS, POLYACRYLAMIDE GEL; FACTOR IXA; FACTOR VIII; HUMANS; MUTANT PROTEINS; POINT MUTATION; PROTEIN STRUCTURE, TERTIARY; TEMPERATURE; THERMODYNAMICS; THROMBIN;

EID: 53449102315     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2008-02-142158     Document Type: Article

References (37)

1. Fay PJ. Activation of factor VIII and mechanisms of cofactor action. Blood Rev. 2004;18:1-15.
2. Fay PJ. Reconstitution of human factor VIII from isolated subunits. Arch Biochem Biophys. 1988; 262:525-531.
3. Ansong C, Miles SM, Fay PJ. Factor VIII A1 domain residues 97-105 represent a light chain-interactive site. Biochemistry. 2006;45:13140-13149.
4. Kaufman RJ. Pipe SW. Regulation of factor VIII expression and activity by von Willebrand factor. Thromb Haemost. 1999;82:201-208.
5. Wakabayashi H, Koszelak ME, Mastri M, Fay PJ. Metal ion-independent association of factor VIII subunits and the roles of calcium and copper ions for cofactor activity and inter-subunit affinity. Biochemistry. 2001;40:10293-10300.
6. Wakabayashi H, Freas J, Zhou Q, Fay PJ. Residues 110-126 in the A1 domain of factor VIII contain a Ca2+ binding site required for cofactor activity. J Biol Chem. 2004;279:12677-12684.
7. Shen BW, Spiegel PC, Chang CH, et al. The tertiary structure and domain organization of coagulation factor VIII. Blood. 2008;111:1240-1247.
8. Fay PJ, Haidaris PJ, Smudzin TM. Human factor VIIIa subunit structure: reconstruction of factor VIIIa from the isolated A1/A3-C1-C2 dimer and A2 subunit. J Biol Chem. 1991;266:8957-8962.
9. Wakabayashi H, Zhou Q, Nogami K, et al. pH-dependent association of factor VIII chains: enhancement of affinity at physiological pH by Cu2 + Biochim Biophys Acta. 2006; 1764:1094-1101.
10. Ansong C, Fay PJ. Factor VIII A3 domain residues 1954-1961 represent an A1 domain-interactive site. Biochemistry. 2005;44:8850-8857.
11. Lollar P, Parker CG. pH-dependent denaturation of thrombin-activated porcine factor VIII. J Biol Chem. 1990;265:1688-1692.
12. Lollar P, Parker ET, Fay PJ. Coagulant properties of hybrid human/porcine factor VIII molecules. J Biol Chem. 1992;267:23652-23657.
13. Fay PJ, BeattieTL, Regan LM, O'Brien LM, Kaufman RJ. Model for the factor VIlladependent decay of the intrinsic factor Xase: role of subunit dissociation and factor IXa-catalyzed proteolysis. J Biol Chem. 1996;271:6027-6032.
14. Pipe SW, Eickhorst AN, McKinley SH, Saenko EL, Kaufman RJ. Mild hemophilia A caused by increased rate of factor VIII A2 subunit dissociation: evidence for nonproteolytic inactivation of factor VIlla in vivo. Blood. 1999;93:176-183.
15. Pipe SW, Saenko EL, EickhorstAN, Kemball-Cook G, Kaufman RJ. Hemophilia A mutations associated with 1-stage/2-stage activity discrepancy disrupt protein-protein interactions within the triplicated A domains of thrombin-activated factor Villa. Blood. 2001;97:685-691.
16. Hakeos WH, Miao H, Sirachainan N, et al. HemophiliaA mutations within the factor VIII A2-A3 subunit interface destabilize factor VIlla and cause one-stage/two-stage activity discrepancy. Thromb Haemost. 2002;88:781-787.
17. Duncan EM, Duncan BM, Tunbridge LJ, Lloyd JV. Familial discrepancy between the one-stage and two-stage factor VIII methods in a subgroup of patients with haemophilia A. Br J Haematol. 1994;87:846-848.
18. Rudzki Z, Duncan EM, Casey GJ, Neumann M, Favaloro EJ, Lloyd JV. Mutations in a subgroup of patients with mild haemophilia Aand a familial discrepancy between the one-stage and twostage factor VIII:C methods. Br J Haematol. 1996;94:400-406.
19. Pemberton S, Lindley P, Zaitsev V, Card G, Tuddenham EG, Kemball-Cook G. A molecular model for the triplicated A domains of human factor VIII based on the crystal structure of human ceruloplasmin. Blood. 1997;89:2413-2421.
20. Wakabayashi H, Fay PJ. Identification of residues contributing to A2 domain-dependent structural stability in factor VIII and factor Villa. J Biol Chem. 2008;283:11645-11651.
21. Sammond DW, Eletr ZM, Purbeck C, Kimple RJ, Siderovski DP, Kuhlman B. Structure-based protocol tor identifying mutations that enhance protein-protein binding affinities. J Mol Biol. 2007; 371:1392-1404.
22. Mimms LT, Zarnpighi G, Nozaki Y, Tanford C, Reynolds JA. Phospholipid vesicle formation and transmembrane protein incorporation using octyl glucoside. Biochemistry. 1981;20:833-840.
23. Doering C, Parker ET, Healey JF, Craddock HN, Barrow RT, Lollar P. Expression and characterization of recombinant murine factor VIII. Thromb Haemost. 2002;88:450-458.
24. Wakabayashi H, Su YC, Ahmad SS, Walsh PN, Fay PJ. A Glu113Ala mutation within a factor VIII Ca(2 +)-binding site enhances cofactor interactions in factor Xase. Biochemistry. 2005;44: 10298-10304.
25. Over J. Methodology of the one-stage assay of Factor VIII (VIII:C). Scand J Haematol Suppl. 1984;41:13-24.
26. Lollar P, Fay PJ, Fass DN. Factor VIII and factor Villa. Methods Enzymol. 1993;222:128-143.
27. Wakabayashi H, Schmidt KM, Fay PJ. Ga(2+) binding to both the heavy and light chains of factor VIII is required for cofactor activity. Biochemistry. 2002;41:8485-8492.
28. Hernker HC, Giesen P, AI Dieri R, et al. Calibrated automated thrombin generation measurement in clotting plasma. Pathophysiol Haemost Thromb. 2003;33:4-15.
29. Hemker HC, Beguin S. Thrombin generation in plasma: its assessment via the endogenous thrombin potential. Thromb Haemost. 1995;74: 134-138.
30. Weiner SJ, Kollman PA. Case DA, et al. A new force field for molecular mechanical simulation of nucleic acids proteins. J Am Chem Soc. 1984; 106:765-784.
31. Swiss Institute of Bioinformatics. UniProtKB/Swiss-Prot Release 55.5 of June 10, 2008, Uni-ProtKB/TrEMBL Release 38.5 of June 10, 2008. http://ca.expasy.org/sprot. Accessed July 2, 2008.
32. Kemball-Cook G, Tuddenham EG, Wacey Al. The factor VIII Structure and Mutation Resource Site: HAMSTeRS version 4. Nucleic Acids Res. 1998; 26:216-219.
33. Kemball-Cook G. MRC Clinical Sciences Centre, Haemophilia A Mutation Database. http://europium.csc.mrc.ac.uk. Accessed July 2. 2008.
34. Pace CN, Shirley BA, McNutt M, Gajiwala K. Forces contributing to the conformational stability of proteins. FASEB J. 1996;10:75-83.
35. Pipe SW, Kaufman RJ. Characterization of a genetically engineered inactivation-resistant coagulation factor Villa. Proc Natl Acad Sci U S A. 1997;94:11851-11856.
36. Gale AJ, Pellequer JL. An engineered interdomain disulfide bond stabilizes human blood coagulation factor VIIIa. J Thromb Haemost. 2003; 1:1966-1971.
37. Radtke KP, Griffin JH, Riceberg J, Gale AJ. Disulfide bond-stabilized factor VIII has prolonged factor Villa activity and improved potency in whole blood clotting assays. J Thromb Haemost. 2007; 5:102-108.